Development of Mitochondria-Targeted PARP Inhibitors
PARP inhibitors are a clinically validated class of anticancer therapeutics that exploit synthetic lethality to target homologous recombination-deficient tumors, such as those carrying BRCA1/2 mutations. Nevertheless, the rational design of mitochondria-targeted PARP inhibitors capable of selective...
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI AG
2026-01-01
|
| Serie: | Biomolecules |
| Soggetti: | |
| Accesso online: | https://www.mdpi.com/2218-273X/16/1/165 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|